Biotech Roll-Up Forms in Autoimmune Space
In a PE-backed biotech roll-up, Rallybio is merging with Candid Therapeutics, supported by a new $505 million financing round. The combined entity will focus on advancing a portfolio of T-cell engagers for autoimmune diseases, showcasing a popular strategy for consolidating and funding clinical-stage assets.
This transaction is structured as a reverse merger, with the publicly-traded Rallybio acquiring the privately-held Candid Therapeutics. Post-merger, the combined entity will operate under the Candid Therapeutics name and trade on Nasdaq with the ticker "CDRX", effectively providing Candid a path to the public markets. The deal values Rallybio at approximately $47.5 million and Candid Therapeutics at $750 million. Upon closing, pre-merger Candid shareholders will own about 57.6% of the new company, investors from the concurrent financing will hold 38.8%, and Rallybio's original equity holders will be left with a residual 3.7% stake. A syndicate of prominent healthcare investors, including Venrock Healthcare Capital Partners, RA Capital Management, and Janus Henderson Investors, led the oversubscribed $505 million financing. This capital injection, combined with existing cash, is expected to provide a pro-forma cash balance of around $700 million, funding operations through 2030. The strategy behind Candid is a classic "roll-up," as the company itself was formed in 2024 through the acquisitions of two other biotechs, Vignette Bio and TRC 2004, to consolidate promising T-cell engager assets. The merger with Rallybio represents the next phase of this consolidation, providing public market access and substantial funding. For Rallybio, this merger follows a period of significant setbacks. The company, which went public in 2021, discontinued its lead drug for a rare maternal-fetal blood disorder in 2025 and executed multiple rounds of layoffs, causing its stock to plummet. This deal offers its remaining shareholders a stake in a well-capitalized clinical-stage company. Candid's lead asset is cizutamig, a bispecific antibody targeting BCMA on B-cells and CD3 on T-cells to treat autoimmune diseases. Having already been tested in 87 patients, it is slated to enter Phase 2 trials for myasthenia gravis and interstitial lung disease in 2026. The pipeline also includes CND261, a CD20-targeted T-cell engager. The transaction taps into a hot therapeutic area, with T-cell engagers (TCEs) expanding from oncology into autoimmune disorders. The global TCE market is projected to grow significantly, with analysts forecasting it to reach $18.8 billion by 2034, reflecting intense R&D and investment interest in the modality.
